ESPERION THERAPS INC
PharmaESPERION THERAPS INC is a pharmaceutical company focused on Cardiovascular. Key products include NEXLETOL.
FDA Novel Drug Designations
(2020)See 1 novel approval →
ESPERION THERAPS INC at a Glance
- Strong track record with 100% execution quality across 23 trials
- Fast trial execution (10 months median completion)
ESPERION THERAPS INC's Key Drugs
ESPERION THERAPS INC's core commercial portfolio centers on NEXLETOL, NEXLIZET, spanning Cardiovascular — its most strategically important drugs approved in the last 15 years.
ESPERION THERAPS INC's Recent FDA Approvals
New NDA/BLA approvals for ESPERION THERAPS INC over the last two years — novel drugs only, excluding generics and label supplements.
ESPERION THERAPS INC's Therapeutic Areas
ESPERION THERAPS INC's approved drugs and pipeline span 1 therapeutic area, led by Cardiovascular, across 0 biologic and 2 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
ESPERION THERAPS INC's Top Competitors
ESPERION THERAPS INC's closest competitors by therapeutic-area and drug-target overlap include Novartis, Merck, and Baxter. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
ESPERION THERAPS INC Pipeline Snapshot
Active clinical trials for ESPERION THERAPS INC across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • NEXLETOL leads revenue
- • 2 key drugs tracked
Trial Catalysts
- • Cardiovascular pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 7/7 completed
- • Speed: 10 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges